Induction of thymic lymphosarcoma and mammary adenocarcinomas in rats by oral administration of the antitumor agent4(5)-(3,3-dimethyl-l-triazeno)imidazole-5(4)-carboxamide

Joseph L. Skibba, E. Ertürk, George T. Bryan

Cancer · 1970 · 30 citations · 26 references

DOIFull text

Open access

Concepts

Abstract

4(5)-(3,3-dimethyl-l-triazeno)imidazole-5(4)-carboxamide (DICNSC 45388)and anticancer drug with activity against rodent and human tumorswas tested for carcinogenic activity by feeding a mean cumulative dose of 740 mg/rat/14 weeks to 24 female Sprague-Dawley weanling rats. The first mammary tumor was palpated 10 weeks after the start of feeding DICand by 18 weekswhen the experiment was terminatedall 24 rats had developed an average of 5 mammary adenocarcinomas. Lymphosarcoma was present in the thymus of all rats and in the spleen (20/24)lymph nodes (18/24)and bone marrow (12/24). Ependymomas of the brain were present in 9 rats and pulmonary alveolar carcinomas in 4 rats. No tumors were found in the negative control group of 24 rats. DIC appears to be a potent chemical carcinogen that may exert its carcinogenic activity by the alkylation of biopolymers.

References

26